Results 131 to 140 of about 16,593 (260)

Fluorescent Diarylethenes With Polar Groups: Synthesis, Spectra, and Optical Microscopy Applications

open access: yesChemistry – A European Journal, EarlyView.
Blinking green and flashing red: photo‐switchable and photo‐activatable probes emitting green and red light were prepared and applied as bioconjugates in super‐resolution optical microscopy. ABSTRACT The use of photoactivatable fluorescent diarylethenes (fDAEs) in biology‐related light microscopy has been restricted by the lack of probes having freely ...
Kakishi Uno   +6 more
wiley   +1 more source

An Orthogonal Way of Writing the Tubulin Code

open access: yesCytoskeleton, EarlyView.
ABSTRACT The Elongator complex has long been characterized for its role in tRNA modification and modulation of protein translation. Beyond these established functions, recent findings reveal an unexpected role for Elongator in directly interacting and tuning microtubule dynamics and properties, broadening its biological significance in eukaryotic cells.
Vicente Jose Planelles‐Herrero   +1 more
wiley   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh   +9 more
wiley   +1 more source

Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding

open access: yesFrontiers in Immunology
BackgroundTumor necrosis factor receptor 2 (TNFR2) is expressed on regulatory T cells (Tregs) and many cancer cells indicating its potential as a therapeutic target.
Liang Huang   +20 more
doaj   +1 more source

CAT‐BLAST: Engineered bacteria for robust targeting and elimination of cancer‐associated fibroblasts

open access: yesiMeta, EarlyView.
Cancer‐associated fibroblasts (CAFs) construct a protective stromal barrier that promotes tumor growth and resistance to therapy. To dismantle this, we developed CAT‐BLAST, an engineered bacterial platform designed to potently eliminate these cells. We engineered a safe, high‐expression E.
Mengdi Xu   +7 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender   +2 more
wiley   +1 more source

In Vitro Self-assembly Study of ZEN/DON Anti-idiotype Nanobody Based on SpyCatcher/SpyTag

open access: yesShipin gongye ke-ji
To improve the immunoassay performance of mycotoxin anti-idiotype nanobody and to realize mimicry of bispecific detected antigens, in this study, anti-idiotype nanobody against zearalenone (ZEN) and deoxynivalenol (DON) were used, and the SpyCatcher ...
Xiao WU   +5 more
doaj   +1 more source

Quantifying Protein–Glycan Interactions Using Native Mass Spectrometry

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT Interactions between glycan‐binding proteins (GBPs) and carbohydrates (glycans) are essential to many biological processes relevant to human health and disease. For most GBPs, however, their glycan interactome—the repertoire of glycans recognized and their specificities—is poorly defined.
Duong T. Bui   +4 more
wiley   +1 more source

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

open access: yesMovement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy